HealthQuill Articles by: HealthQuill
UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza viruses.
Drugs Health Medical

UK’s DIOSynVax develops single candidate vaccine for bird flu virus

UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza

Read More
cigarette smoke
Drugs Health Pharma

US drug regulator clears Qnovia’s nicotine inhaler for clinical testing

HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US

Read More
British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic disorder.
Drugs Health Medical

AstraZeneca in $1.92 million deal with HK-listed CSPC Pharmaceutical

British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic

Read More
Extreme warming in the Antarctic Peninsula has increased the vegetation cover in the region by more than tenfold over the last four decades, according to researchers from the universities of Exeter and Hertfordshire and the British Antarctic Survey.
Climate Health Medical

Vegetation cover in Antarctic Peninsula increases 10-fold in last four yrs: Study

Extreme warming in the Antarctic Peninsula has increased the vegetation cover in the region by more than tenfold over the last four decades,

Read More
he Democratic Republic of the Congo has started mpox vaccination aiding efforts to halt the spread of the viral disease, according to the World Health Organization.
Drugs Health Medical

Congo begins mpox vaccination in eastern region, roll-outs in 11 provinces

he Democratic Republic of the Congo has started mpox vaccination aiding efforts to halt the spread of the viral disease, according to the

Read More
More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state actors, according to a Global Witness report.
Climate Health Pharma

More than 200 land defenders died globally in 2023, Colombia deadliest

More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state

Read More
Global corporations worldwide are now adapting to a "new normal," where WFH is becoming standard practice, either fully or partially. While seeking a "new normal," there is growing concern about mental health outcomes associated with WFH.  A study examining WFH experiences during lockdown found that most respondents reported more positive than negative experiences. 
Drugs Health Medical Opinion

Opinion: Work from home debate rages on as Mental Health Day nears

By Aparna S As we inch toward October 10, Mental Health Day, the ‘Workplace Mental Health’ theme for 2024 needs to be put

Read More
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Drugs Health Pharma

Johnson & Johnson stops mid-stage trial of drug for dengue prevention

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

Read More
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's immune system to attack red blood cells, for an upfront $825 million.
Drugs Health Pharma

Recordati buys Sanofi’s drug for autoimmune disease for $825 million

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's

Read More
Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments globally.
Climate Drugs Pharma

Denmark’s Novo Nordisk to invest $158 million in Brazil insulin facility

Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments

Read More